Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study.
Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, Chen MH.
Chiang NJ, et al. Among authors: chen sc, chen lt, chen sj, chen mh.
Clin Cancer Res. 2022 Oct 3;28(19):4248-4257. doi: 10.1158/1078-0432.CCR-22-1152.
Clin Cancer Res. 2022.
PMID: 35849151
Free PMC article.
Clinical Trial.